BioCentury
ARTICLE | Deals

AstraZeneca adds RNA-modifying targets to oncology pipeline via Accent deal

June 5, 2020 2:13 AM UTC

Less than two months after its series B round, Accent has added $55 million to its balance sheet after partnering with AstraZeneca to co-develop up to three of its cancer programs targeting an RNA-modifying protein.

When it launched in 2018 with a $40 million series A round led by The Column Group and Atlas Venture, Accent Therapeutics Inc. was among the first companies to begin developing compounds against RNA epigenetic proteins, a subset of RNA-modifying proteins that help control which proteins are made as well as when protein translation occurs (see “Accent on RNA”)...